Taro Pharmaceutical Industries Ltd. (TARO)

100.32
0.18 0.18
NYSE : Health Technology
Prev Close 100.14
Open 101.34
Day Low/High 99.69 / 103.28
52 Wk Low/High 93.01 / 128.46
Volume 79.11K
Avg Volume 126.70K
Exchange NYSE
Shares Outstanding 40.10M
Market Cap 4.07B
EPS 11.10
P/E Ratio 19.51
Div & Yield N.A. (N.A)

Latest News

Taro Provides Results For September 30, 2017

Taro Provides Results For September 30, 2017

November 7, 2017-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and six months ended September 30, 2017.

Taro To Announce Second Quarter Results On November 7, 2017

Taro To Announce Second Quarter Results On November 7, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("TARO" or the "Company") announced today that it plans to release its financial results for the quarter and six months ended September 30, 2017, on Tuesday, November 7, 2017.

Taro Announces Joining Of CEO

Taro Announces Joining Of CEO

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that Mr.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BBSI, CAFD, CNXC, GNRT, GSBD, MCRN, RLGY, SBLK Downgrades: BGFV, BWINA, DGICA, HLIT, JACK, MDCO, RRGB, SOHO, TARO, TNC, VSAT, VSI, XRAY Initiations: LNTH, VTVT, WING Read on to get TheStreet Quant Ratings' detailed report:

Taro Provides Results For Quarter Ended June 2017

Taro Provides Results For Quarter Ended June 2017

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter ended June 30, 2017.

Taro To Announce First Quarter Results On August 8, 2017

Taro To Announce First Quarter Results On August 8, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2017, after the close of market on Tuesday, August 8, 2017.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATHN, NCR, PII, PM, TARO Downgrades: PBNC, SCS Initiations: HRI, SUPV Read on to get TheStreet Quant Ratings' detailed report:

Taro Annual Report On Form 20-F Available For Fiscal Year Ended March 31, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO, "Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission (the "SEC"), is available...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: JACK, OXM Downgrades: ANF, ASND, EQM, IMKTA, KR, TARO Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.

Taro Provides Results For Year Ended March 31, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and fiscal year ended March 31, 2017.

Taro To Announce Results For Year Ended March 31, 2017 On May 22, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the fiscal year ended March 31, 2017, on Monday, May 22, 2017.

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CNQ, JNP, QIWI, TARO Downgrades: IRIX, PFIN, TSCO Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Taro Provides Results For December 31, 2016

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and nine months ended December 31, 2016.

Taro To Announce Third Quarter Results On February 9, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2016, after the close of market on Thursday, February 9, 2017.

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Demographic trends that boosted big gains in prior years haven't gone away.

Taro Announces Sale Of U.S. Rights To Keveyis® To Strongbridge Biopharma Plc

Taro Announces Sale Of U.S. Rights To Keveyis® To Strongbridge Biopharma Plc

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced the sale of U.

Impax Searches for a New CEO

Impax Searches for a New CEO

Impax Laboratories CEO G. Frederick Wilkinson steps down amid a Department of Justice generic price-fixing investigation. J. Kevin Buchi, who joined the board last month, was tapped as interim CEO.

Bearish Bets: A Drug Maker, a Mexican Airline and Other Stocks That Look Good Short

MLNX, TARO, VLRS, DL and GIMO all were recently downgraded by TheStreet's Quant Ratings.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Taro Pharmaceutical Industries Ltd.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Taro Pharmaceutical Industries Ltd.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Taro Pharmaceutical Industries Ltd.

DOJ Files Charges in Generic Drug Price-Fixing Investigation

DOJ Files Charges in Generic Drug Price-Fixing Investigation

Shares of leading generics fall as more charges are expected.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCRH, BGFV, CHTR, CTS, HLT, HZO, JRVR, MOMO, NYRT, PERY, VLP Downgrades: DL, MLNX, SGMA, SPKE, TARO, VLRS Initiations: AAAP, EQBK, VYGR Read on to get TheStreet Quant Ratings' detailed report:

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Taro Pharmaceutical Industries Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 27, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Taro Pharmaceutical Industries Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of December 27, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Taro Pharmaceutical Industries Ltd.

TARO SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Taro Pharmaceutical Industries Ltd. And A Lead Plaintiff Deadline Of December 27, 2016

TARO SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Taro Pharmaceutical Industries Ltd. And A Lead Plaintiff Deadline Of December 27, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Taro Pharmaceutical Industries Ltd.

Taro Announces Appointment Of Interim CEO

Taro Announces Appointment Of Interim CEO

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") announced today that its Board of Directors has appointed Mr.

TheStreet Quant Rating: C+ (Hold)